/
KALA
$2.09-$0.43 (-17.06%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$46.8M
19M shares
52-week range
$2.02 – $1,030.00
0% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
12.17%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-13234.67
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6.1M | $6.4M | $11.2M | $3.9M | $0 | $0 | $0 |
| Cost of revenue | $955.0K | $2.8M | $3.2M | $4.1M | $2.6M | $303.0K | $259.0K | $0 |
| Gross profit | −$955.0K | $3.2M | $3.2M | $7.1M | $1.3M | −$303.0K | −$259.0K | $0 |
| Gross margin | — | 53.1% | 50.1% | 63.5% | 34.2% | — | — | — |
| R&D | $29.3M | $27.0M | $18.4M | $11.5M | $17.7M | $18.6M | $21.8M | $18.8M |
| Operating income | −$64.7M | −$88.2M | −$96.2M | −$109.4M | −$81.4M | −$39.2M | −$40.4M | −$39.2M |
| EBITDA | −$63.8M | −$85.6M | −$93.4M | −$132.0M | −$36.7M | −$36.1M | −$32.5M | −$23.4M |
| Net income | −$66.7M | −$94.3M | −$104.3M | −$142.6M | −$44.8M | −$42.2M | −$38.5M | −$27.0M |
| Net margin | — | -1553.3% | -1639.8% | -1268.7% | -1151.6% | — | — | — |
| EPS (diluted) | -124.73 | -149.06 | -99.59 | -109.35 | -29.48 | -17.35 | -6.98 | -3.31 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $25M | $-26.50 | $-26.50–$-26.50 | 1 |
| 2027 | $26M | $-20.00 | $-20.00–$-20.00 | 1 |
| 2028 | $134M | $-9.00 | $-9.00–$-9.00 | 1 |
| 2029 | $229M | $-8.50 | $-8.50–$-8.50 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.81
Price
$2.09
Implied downside
-61%
Peer comparison
KALA BIO, Inc. Common Stock
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
www.kalarx.com- Employees
- 6
- IPO / List date
- Jul 20, 2017
- HQ
- ARLINGTON, MA
Held by traders on TradeandTell
No one on the platform currently holds KALA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in KALA as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-05-11 | 1-for-50reverse |
| 2022-10-21 | 1-for-50reverse |
| 2022-08-26 | 1.001-for-1 |
Recent trades on TradeandTell
No one on the platform has traded KALA yet.
